[Study on lasting immunity in previously treated persons against rabies and investigation of booster effect of Vero rabies vaccine]

Human rabies is preventable by prompt post-exposure prophylaxis. The total number of rabies vaccine doses administered during post-exposure prophylaxis is 5; given on days 0, 3, 7, 14 and 30. The aim of this study was to measure the durability of rabies neutralizing antibody in exposed persons treated 14-17 years ago and to investigate the effect of 2 boosters of rabies vaccine. This study was conducted in 2 phases. In phase 1 blood samples were taken from 100 rabies vaccine recipients 14-17 years after they had received the vaccine. In the 2nd stage of the studies 30 volunteers from the first phase of the study were divided into 2 groups of 15 subjects each; the first group was given 2 booster doses of the vaccine intra-dermally on days 0 and 3. In the 2[nd] group the 2 doses were administered through the intramuscular route; blood samples were collected 10 days after the booster doses. Rapid Focus Fluorescent Inhibition Test [RFFIT] was used for measuring the antibodies in both phases. The rabies neutralizing antibody was detected in the sera of all 100 individuals who had received the rabies vaccine, 85% of whom demonstrated titers ?0.5 IU/ml. In the groups who received the booster doses, serology results demonstrated higher rabies neutralizing antibody titers in persons who had received the two booster injections intradermally. This study confirms the persistence of rabies neutralizing antibody for at least 14 years after a full course of primary post-exposure prophylaxis; furthermore two booster inoculations of Vero rabies vaccine on days 0 and 3, given intradermally resulted in a sharp increase in the level of antibodies, indicating that two boosters could protect against rabies after a repeat exposure

[Clinical and molecular investigation of friedreich ataxia in Iranian patients]

Friedreich ataxia [FA] is an autosomal recessive disorder that caused by the expansion of GAA trinucleotide repeat in the first intron of gene X25 [1]. FA is characterized by progressive ataxia and deep tendon areflexia in the lower limbs, dysarthria, skeletal deformities, Cardiomyopathy, muscle weakness and diabetes mellitus may be also found. Cardiomyopathy occurs in almost patients with FA [2]. Cardiomyopathy is the most cause of death in FA patients [3]. Aim of present study was to evaluate the size of GAA repeat and it's correlation with age at onset and cardiomyopathy in these patients. Long PCR testing subsequently confirmed the diagnosing of FA and by identification of GAA repeat, an inverse correlation between size of repeat and age at onset and cardiomyopathy was found